These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 27514314)

  • 21. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
    Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
    J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy.
    Yamazaki H; Nakamura S; Suzuki G; Yoshida K; Yoshioka Y; Koizumi M; Ogawa K
    Anticancer Res; 2015 Oct; 35(10):5167-77. PubMed ID: 26408674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of linac-based image-guided hypofractionated prostate radiotherapy.
    Pawlicki T; Kim GY; Hsu A; Cotrutz C; Boyer AL; Xing L; King CR; Luxton G
    Med Dosim; 2007; 32(2):71-9. PubMed ID: 17472885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes.
    Wu R; Woodford H; Capp A; Hunter P; Cowin G; Tai KH; Nguyen PL; Chong P; Martin J
    Radiat Oncol; 2015 Nov; 10():243. PubMed ID: 26607977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets in Prostate Cancer.
    Bossart EL; Stoyanova R; Sandler K; Studenski M; Orman A; Abramowitz M; Pollack A
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):827-34. PubMed ID: 27020109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible?
    Amini A; Westerly DC; Waxweiler TV; Ryan N; Raben D
    Med Dosim; 2015; 40(3):256-61. PubMed ID: 25824420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
    Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
    BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience.
    Barbosa Neto O; Souhami L; Faria S
    Cancer Radiother; 2015 Oct; 19(6-7):431-6. PubMed ID: 26278988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery.
    Ghilezan M; Yan D; Liang J; Jaffray D; Wong J; Martinez A
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1602-10. PubMed ID: 15590192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
    Marvaso G; Corrao G; Repetti I; Lorubbio C; Bellerba F; Zaffaroni M; Vincini MG; Zerini D; Alessi S; Luzzago S; Mistretta FA; Fodor C; Cambria R; Cattani F; Ceci F; Musi G; De Cobelli O; Zilli T; Gandini S; Orecchia R; Petralia G; Jereczek-Fossa BA
    World J Urol; 2024 Mar; 42(1):169. PubMed ID: 38492078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.
    Wong WW; Schild SE; Vora SA; Ezzell GA; Nguyen BD; Ram PC; Roarke MC
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e423-9. PubMed ID: 21477947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction.
    Musunuru HB; Loblaw A
    Future Oncol; 2015; 11(5):819-31. PubMed ID: 25757684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):617-23. PubMed ID: 22079736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
    Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
    Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.
    Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N
    Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.
    Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Cambria R; Garibaldi C; Tagaste B; Vavassori A; Cattani F; Alterio D; Gherardi F; Serafini F; Rocco B; Musi G; De Cobelli O; Orecchia R
    Urol Oncol; 2011; 29(5):523-32. PubMed ID: 20005749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New methods in the treatment of localized prostate cancer: use of dynamic arc therapy and kV cone-beam CT positioning].
    Szappanos S; Farkas R; Lőcsei Z; László Z; Kalincsák J; Bellyei S; Sebestyén Z; Csapó L; Sebestyén K; Halász J; Musch Z; Beöthe T; Farkas L; Mangel L
    Orv Hetil; 2014 Aug; 155(32):1265-72. PubMed ID: 25087218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.